203 related articles for article (PubMed ID: 17584044)
1. Management of dyslipidemia in the metabolic syndrome.
Tan KC
Cardiovasc Hematol Disord Drug Targets; 2007 Jun; 7(2):99-108. PubMed ID: 17584044
[TBL] [Abstract][Full Text] [Related]
2. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Nesto RW
Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
[TBL] [Abstract][Full Text] [Related]
3. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
Tenenbaum A; Fisman EZ; Motro M; Adler Y
Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960
[TBL] [Abstract][Full Text] [Related]
4. Dyslipidemia in the metabolic syndrome in children.
Gidding SS
J Cardiometab Syndr; 2006; 1(4):282-5. PubMed ID: 17679808
[TBL] [Abstract][Full Text] [Related]
5. Management of dyslipidemia in the metabolic syndrome: recommendations of the Spanish HDL-Forum.
Ascaso J; Gonzalez Santos P; Hernandez Mijares A; Mangas Rojas A; Masana L; Millan J; Pallardo LF; Pedro-Botet J; Perez Jimenez F; Pintó X; Plaza I; Rubiés J; Zúñiga M
Am J Cardiovasc Drugs; 2007; 7(1):39-58. PubMed ID: 17355165
[TBL] [Abstract][Full Text] [Related]
6. Targeting dyslipidemia in the metabolic syndrome: an update.
Paraskevas KI; Karatzas G; Pantopoulou A; Iliopoulos DG; Perrea D
Curr Vasc Pharmacol; 2010 Jul; 8(4):450-63. PubMed ID: 19485929
[TBL] [Abstract][Full Text] [Related]
7. [How to treat dyslipidemia in patients with metabolic syndrome].
Soška V
Vnitr Lek; 2015; 61(7-8):721-4. PubMed ID: 26375703
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular disease risk of type 2 diabetes mellitus and metabolic syndrome: focus on aggressive management of dyslipidemia.
Falko JM; Moser RJ; Meis SB; Caulin-Glaser T
Curr Diabetes Rev; 2005 May; 1(2):127-35. PubMed ID: 18220588
[TBL] [Abstract][Full Text] [Related]
9. The metabolic basis of atherogenic dyslipidemia.
Vinik AI
Clin Cornerstone; 2005; 7(2-3):27-35. PubMed ID: 16473258
[TBL] [Abstract][Full Text] [Related]
10. Dyslipidemia in the metabolic syndrome: clinical implications and management.
Hafidh SA; Lavie CJ; Burns BP; Khan SS; Alpert MA
Minerva Cardioangiol; 2006 Apr; 54(2):215-27. PubMed ID: 16778753
[TBL] [Abstract][Full Text] [Related]
11. Atherogenic dyslipidemia in the cardiometabolic syndrome.
Govindarajan G; Chowdhury N; Flaker G
J Cardiometab Syndr; 2006; 1(2):153-5. PubMed ID: 17679818
[No Abstract] [Full Text] [Related]
12. Prevalence of low high-density lipoprotein cholesterol and hypertriglyceridaemia in patients treated with hypolipidaemic drugs.
Laforest L; Souchet T; Moulin P; Ritleng C; Desamericq G; Le Jeunne P; Schwalm MS; Van Ganse E
Arch Cardiovasc Dis; 2009 Jan; 102(1):43-50. PubMed ID: 19233108
[TBL] [Abstract][Full Text] [Related]
13. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome.
Grundy SM
Am J Cardiol; 1998 Feb; 81(4A):18B-25B. PubMed ID: 9526809
[TBL] [Abstract][Full Text] [Related]
14. Journey through cholesteryl ester transfer protein inhibition: from bench to bedside.
Karalis I; Rensen PC; Jukema JW
Circ Cardiovasc Qual Outcomes; 2013 May; 6(3):360-6. PubMed ID: 23674310
[No Abstract] [Full Text] [Related]
15. Effect of rosuvastatin on dyslipidemia and other parameters associated with metabolic syndrome in Saudi patients.
Rafeeq MM; Habib HS; Murad H; Gari MA; Gazzaz ZJ
Niger J Clin Pract; 2017 Apr; 20(4):445-453. PubMed ID: 28406125
[TBL] [Abstract][Full Text] [Related]
16. Successful control of dyslipidemia in patients with metabolic syndrome: focus on lifestyle changes.
Stone NJ
Clin Cornerstone; 2006; 8 Suppl 1():S15-20. PubMed ID: 16903165
[TBL] [Abstract][Full Text] [Related]
17. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management.
Cardenas GA; Lavie CJ; Cardenas V; Milani RV; McCullough PA
Rev Cardiovasc Med; 2008; 9(4):239-58. PubMed ID: 19122582
[TBL] [Abstract][Full Text] [Related]
18. Duality of statin action on lipoprotein subpopulations in the mixed dyslipidemia of metabolic syndrome: Quantity vs quality over time and implication of CETP.
Chapman MJ; Orsoni A; Robillard P; Therond P; Giral P
J Clin Lipidol; 2018; 12(3):784-800.e4. PubMed ID: 29574070
[TBL] [Abstract][Full Text] [Related]
19. The role of fibrate treatment in dyslipidemia: an overview.
Katsiki N; Nikolic D; Montalto G; Banach M; Mikhailidis DP; Rizzo M
Curr Pharm Des; 2013; 19(17):3124-31. PubMed ID: 23317397
[TBL] [Abstract][Full Text] [Related]
20. Obesity and dyslipidemia.
Repas T
S D Med; 2011 Jul; 64(7):241-3, 245, 247 passim. PubMed ID: 21848021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
